Clinical Trial

TACTIC-HF: Sequential Diuretic Strategies in Ambulatory Worsening Heart Failure

Study acronym: TACTIC-HF
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
TACTIC-HF is a prospective randomized crossover trial designed to compare three ambulatory diuretic strategies in patients with worsening heart failure treated in a specialized heart failure day-hospital program. Participants will receive sequential treatment with: 1. intravenous furosemide alone, 2. intravenous furosemide combined with oral acetazolamide, and 3. intravenous furosemide combined with oral hydrochlorothiazide. The primary objective is to compare short-term natriuretic response between strategies. Secondary objectives include assessment of urine output, congestion parameters, and renal/electrolyte safety. Each participant will undergo repeated outpatient treatment sessions separated by washout periods, with standardized clinical and laboratory monitoring performed during each visit. The study aims to evaluate pragmatic and clinically applicable ambulatory decongestion strategies using approved therapies commonly available in real-world practice.
Trial Details
NCT Number NCT07593612
Lead Sponsor Lucrecia Maria Burgos
Conditions Acute Heart Failure (AHF)
Enrollment 60 participants
Start Date 2026-06-15
Primary Completion 2027-01-15 (estimated)
Study Completion 2027-01-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-18